Archive | Biopharmaceuticals Portfolio

Risk Off On Biotech Trades-BIIB, GILD, XBI…Update-2

Update 3/25 Mid-Day Trading NAZ Off 1.55% at 4917 “Bubble Talk” Picking Up-Mid Caps Vulnerable Biotech sector selling picked up today with a dramatic shift in sentiment exacerbated by an overall weak market. Also durable goods fell unexpectedly 1.4% in February indicating weak global growth.Technology was the weakest sector down 1.74% but the resilient healthcare […]

Continue Reading 0

NASDAQ Up -Biogen Idec Triggers Rally In Biotech

Biotech Stocks Are Soaring In Pre-Market Update at Mid Morning NASDAQ Up 39 to 5031 ¬†Healthcare Stocks Continue To Lead Biogen Idec (BIIB) Up 10% On Alzheimer Disease Phase 1 Data Encouraging Phase I data on aducanumab with 166 patients shows acceptable safety and amyloid plaque reduction prompts Company to skip early stage study and […]

Continue Reading 0

Biotech Bull Market-Trends to Watch #2: ETF Review-FBT XBI

Biotech and Healthcare ETFs Hit An All Time High–Another Rally Coming Today 3/20 M&A: Recent buy-outs of Cubist (CBST) for $9.5B and Pharmacyclics (PCYC) for $21B have raised the valuation bar. The healthcare sector remains strong and biopharmaceuticals are key to sales growth. Breakthroughs in genomics, targeted oncology and HCV drugs are blockbuster growth areas. […]

Continue Reading 0

Rayno Life Science Portfolios: AMGN,CLVS,ILMN,RGEN,TMO…Update 3/18

March 18-Stealth Rally With A Tempered Tape In Biotech NASDAQ up 0.92% Biotech stocks lagged the surprising FED rally today maybe because money was moving to other sectors.This bears close watching because only this week biotech stocks hit a new high.Money may be moving to lagging sectors like energy up 2.92% today. Nonetheless healthcare remained […]

Continue Reading 0

Rayno Life Sciences DX and Tools Update: 2015 Q1 Winners ALR,FMI,HOLX

Diagnostic Stocks rally with NASDAQ and Small Caps -IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after the JPMorgan Conference. Nonetheless the sector is attractive longer term […]

Continue Reading